Brain drug developer MapLight Therapeutics lost two-thirds of its market value Monday after unveiling clinical trial results that, while positive, raised doubts about whether one of its experimental ...

Argenx will acquire Forte Biosciences, the developer of an autoimmune disease drug that’s shown early promise, in a deal worth up to $2.2 billion. The Netherlands-based company said Monday it will ...

Today, a brief rundown of news involving Capricor Therapeutics and Legend Biotech, as well as updates from AstraZeneca, Outlook Therapeutics and Otsuka Pharmaceutical that you may have missed.

Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company ...

The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future ...

Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a ...

The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most ...

In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of four peptides despite a ...

The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions ...

Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in ...

The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British ...

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it ...